Iruzid 20 mg/12,5 mg tablete
Name | Iruzid 20 mg/12,5 mg tablete |
---|---|
Marketing Authorisation Number | HR-H-962764695 |
Active Substance | lizinopril dihidrat hidroklorotiazid |
Composition | jedna tableta sadrži 20 mg lizinoprila u obliku lizinopril dihidrata i 12,5 mg hidroklorotiazida |
Pharmaceutical Form | tableta |
Packaging [MA Number for Packaging] | 30 tableta u blisteru, u kutiji [HR-H-962764695-01] 60 tableta u blisteru, u kutiji [HR-H-962764695-02] |
Manufacturer | Belupo lijekovi i kozmetika d.d., Koprivnica, Hrvatska |
Marketing Authorisation Holder | Belupo lijekovi i kozmetika d.d., Ulica Danica 5, Koprivnica, Hrvatska |
Marketing Authorisation Date | 22.12.2016 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/16-02/73 |
Registration Number | 381-12-01/30-16-03 |
Prescription | na recept |
Type of prescription | ponovljivi recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | C09BA03 |
Medicinal product marketed in the Croatia | Da |
SmPC | download |
PL | download |
Direct Healthcare Professional Communication
Name | Date | Download |
---|---|---|
Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |